

# Dengue Fever (DF)- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/D079104FD09EN.html>

Date: July 2019

Pages: 140

Price: US\$ 5,980.00 (Single User License)

ID: D079104FD09EN

## Abstracts

### Report Summary

'Dengue Fever (DF)- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

### Dengue Fever (DF) Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Dengue Fever (DF) in the US, Europe, and Japan are also provided in the report.

## Dengue Fever (DF) Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

## Dengue Fever (DF) Product Profiles & Analysis

This part of the Dengue Fever (DF) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

## Dengue Fever (DF) Market Outlook

The Dengue Fever (DF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

## Dengue Fever (DF) Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and

the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Dengue Fever (DF) Report Insights

Patient Population in Dengue Fever (DF)

Therapeutic Approaches in Dengue Fever (DF)

Dengue Fever (DF) Pipeline Analysis

Dengue Fever (DF) Market Size and Trends

Dengue Fever (DF) Market Opportunities

Impact of upcoming Therapies in Dengue Fever (DF)

Dengue Fever (DF) Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Dengue Fever (DF) Report Assessment

Current Treatment Practices in Dengue Fever (DF)

Unmet Needs in Dengue Fever (DF)

Detailed Dengue Fever (DF) Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Dengue Fever (DF) market

Organize sales and marketing efforts by identifying the best opportunities for Dengue Fever (DF) market

To understand the future market competition in the Dengue Fever (DF) market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Contents

### **1 KEY INSIGHTS**

### **2 DENGUE FEVER (DF) MARKET OVERVIEW AT A GLANCE**

2.1 Market Share (%) Distribution of Dengue Fever (DF) in 2018

2.2 Market Share (%) Distribution of Dengue Fever (DF) in 2028

### **3 DENGUE FEVER (DF): DISEASE BACKGROUND AND OVERVIEW**

3.1 Introduction

3.2 Symptoms

3.3 Etiology

3.4 Risk Factor

3.5 Pathophysiology

3.6 Diagnosis

3.7 Treatment

### **4 EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Dengue Fever (DF) in 7MM

4.3. Total Prevalent Patient Population of Dengue Fever (DF) in 7MM – By Countries

### **5 EPIDEMIOLOGY OF DENGUE FEVER (DF) BY COUNTRIES (2016-2028)**

5.1 United States- Epidemiology (2016-2028)

5.1.1 Assumptions and Rationale

5.1.2 Prevalent/Incident Cases of Dengue Fever (DF) in the United States

5.1.3 Sub-Type Specific cases of Dengue Fever (DF) in the United States

5.1.4 Sex- Specific Cases of Dengue Fever (DF) in the United States

5.1.5 Diagnosed Cases of Dengue Fever (DF) in the United States

5.1.6 Treatable Cases of Dengue Fever (DF) in the United States

5.2 EU5 Countries

5.2.1 Germany

5.2.1.1 Assumptions and Rationale

5.2.1.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the Germany

5.2.1.3 Sub-Type Specific cases of Dengue Fever (DF) in the Germany

- 5.2.1.4 Sex- Specific Cases of the Dengue Fever (DF) in the Germany
- 5.2.1.5 Diagnosed Cases of the Dengue Fever (DF) in the Germany
- 5.2.1.6 Treatable Cases of the Dengue Fever (DF)
- 5.2.2 France
  - 5.2.2.1 Assumptions and Rationale
  - 5.2.2.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the France
  - 5.2.2.3 Sub-Type Specific cases of Dengue Fever (DF) in the France
  - 5.2.2.4 Sex- Specific Cases of the Dengue Fever (DF) in the France
  - 5.2.2.5 Diagnosed Cases of the Dengue Fever (DF) in the France
  - 5.2.2.6 Treatable Cases of the Dengue Fever (DF)
- 5.2.3 Italy
  - 5.2.3.1 Assumptions and Rationale
  - 5.2.3.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the Italy
  - 5.2.3.3 Sub-Type Specific cases of Dengue Fever (DF) in the Italy
  - 5.2.3.4 Sex- Specific Cases of the Dengue Fever (DF) in the Italy
  - 5.2.3.5 Diagnosed Cases of the Dengue Fever (DF) in the Italy
  - 5.2.3.6 Treatable Cases of the Dengue Fever (DF)
- 5.2.4 Spain
  - 5.2.4.1 Assumptions and Rationale
  - 5.2.4.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the Spain
  - 5.2.4.3 Sub-Type Specific cases of Dengue Fever (DF) in the Spain
  - 5.2.4.4 Sex- Specific Cases of the Dengue Fever (DF) in the Spain
  - 5.2.4.5 Diagnosed Cases of the Dengue Fever (DF) in the Spain
  - 5.2.4.6 Treatable Cases of the Dengue Fever (DF)
- 5.2.5 United Kingdom
  - 5.2.5.1 Assumptions and Rationale
  - 5.2.5.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the United Kingdom
  - 5.2.5.3 Sub-Type Specific cases of Dengue Fever (DF) in the United Kingdom
  - 5.2.5.4 Sex- Specific Cases of the Dengue Fever (DF) in the United Kingdom
  - 5.2.5.5 Diagnosed Cases of the Dengue Fever (DF) in the United Kingdom
  - 5.2.5.6 Treatable Cases of the Dengue Fever (DF)
- 5.3 Japan
  - 5.3.1 Assumptions and Rationale
  - 5.3.2 Prevalent/Incident Cases of the of Dengue Fever (DF) in the Japan
  - 5.3.3 Sub-Type Specific cases of Dengue Fever (DF) in the Japan
  - 5.3.4 Sex- Specific Cases of the Dengue Fever (DF) in the Japan
  - 5.3.5 Diagnosed Cases of the Dengue Fever (DF) in the Japan
  - 5.3.6 Treatable Cases of the Dengue Fever (DF)

## **6 CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1 Treatment Algorithm
- 6.2 Treatment Guidelines

## **7 UNMET NEEDS**

## **8 MARKETED PRODUCT**

- 8.1 Drug A: Company
  - 8.1.1 Drug Description
  - 8.1.2 Mechanism of Action
  - 8.1.3 Clinical Trials Details
  - 8.1.4 Advantages & Disadvantages
  - 8.1.5 Safety and Efficacy
  - 8.1.6 Product Profile
- 8.2 Drug B: Company
  - 8.2.1 Drug Description
  - 8.2.2 Mechanism of Action
  - 8.2.3 Clinical Trials Details
  - 8.2.4 Advantages & Disadvantages
  - 8.2.5 Safety and Efficacy
  - 8.2.6 Product Profile
- 8.3 Drug C: Company
  - 8.3.1 Drug Description
  - 8.3.2 Mechanism of Action
  - 8.3.3 Clinical Trials Details
  - 8.3.4 Advantages & Disadvantages
  - 8.3.5 Safety and Efficacy
  - 8.3.6 Product Profile
- 8.4 Drug D: Company
  - 8.4.1 Drug Description
  - 8.4.2 Mechanism of Action
  - 8.4.3 Clinical Trials Details
  - 8.4.4 Advantages & Disadvantages
  - 8.4.5 Safety and Efficacy
  - 8.4.6 Product Profile
- 8.5 Drug E: Company
  - 8.5.1 Drug Description

- 8.5.2 Mechanism of Action
- 8.5.3 Clinical Trials Details
- 8.5.4 Advantages & Disadvantages
- 8.5.5 Safety and Efficacy
- 8.5.6 Product Profile

#### 8.6 : Company

- 8.6.1 Drug Description
- 8.6.2 Mechanism of Action
- 8.6.3 Clinical Trials Details
- 8.6.4 Advantages & Disadvantages
- 8.6.5 Safety and Efficacy
- 8.6.6 Product Profile

#### 8.7 : Company

- 8.7.1 Drug Description
- 8.7.2 Mechanism of Action
- 8.7.3 Clinical Trials Details
- 8.7.4 Advantages & Disadvantages
- 8.7.5 Safety and Efficacy
- 8.7.6 Product Profile

#### 8.8 : Company

- 8.8.1 Drug Description
- 8.8.2 Mechanism of Action
- 8.8.3 Clinical Trials Details
- 8.8.4 Advantages & Disadvantages
- 8.8.5 Safety and Efficacy
- 8.8.6 Product Profile

## 9 EMERGING DRUGS

### 9.1 Key Cross Competition

#### 9.2 Emerging company

- 9.2.1 Emerging Drug A: Company
  - 9.2.1.1 Other Development Activities
  - 9.2.1.2 Clinical Development
  - 9.2.1.3 Clinical Trials Information
  - 9.2.1.4 Safety and Efficacy
  - 9.2.1.5 Advantages and Disadvantages
  - 9.2.1.6 Product Profile
- 9.2.2 Emerging Drug B: Company



- 9.2.2.1 Other Development Activities
- 9.2.2.2 Clinical Development
- 9.2.2.3 Clinical Trials Information
- 9.2.2.4 Safety and Efficacy
- 9.2.2.5 Advantages and Disadvantages
- 9.2.2.6 Product Profile
- 9.2.3 Emerging Drug C: Company
  - 9.2.3.1 Other Development Activities
  - 9.2.3.2 Clinical Development
  - 9.2.3.3 Clinical Trials Information
  - 9.2.3.4 Safety and Efficacy
  - 9.2.3.5 Advantages and Disadvantages
  - 9.2.3.6 Product Profile
- 9.2.4 Emerging Drug D: Company
  - 9.2.4.1 Other Development Activities
  - 9.2.4.2 Clinical Development
  - 9.2.4.3 Clinical Trials Information
  - 9.2.4.4 Safety and Efficacy
  - 9.2.4.5 Advantages and Disadvantages
  - 9.2.4.6 Product Profile
- 9.2.5 Emerging Drug E: Company
  - 9.2.5.1 Other Development Activities
  - 9.2.5.2 Clinical Development
  - 9.2.5.3 Clinical Trials Information
  - 9.2.5.4 Safety and Efficacy
  - 9.2.5.5 Advantages and Disadvantages
  - 9.2.5.6 Product Profile

## **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Dengue Fever (DF)
- 10.2 7MM Percentage Share of Drugs Marketed for Dengue Fever (DF)
- 10.3 7MM Market Sales of Dengue Fever (DF) by Products

## **11 THE UNITED STATES MARKET OUTLOOK**

- 11.1 Market Size of Dengue Fever (DF) in United States
- 11.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in United States
- 11.3 Market Sales of Dengue Fever (DF) by Products in United States

## 11.4 Analysis of Upcoming Therapies and Impact on the Market

## 12 EU5 COUNTRIES MARKET OUTLOOK

### 12.1 Market Size of Dengue Fever (DF) in EU5

### 12.2 Market Size of Dengue Fever (DF) in Germany

#### 12.2.1 Market Size of Dengue Fever (DF) in Germany

#### 12.2.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in Germany

#### 12.2.3 Market Sales of Dengue Fever (DF) by Products in Germany

#### 12.2.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.3 Market Size of Dengue Fever (DF) in France

#### 12.3.1 Market Size of Dengue Fever (DF) in France

#### 12.3.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in France

#### 12.3.3 Market Sales of Dengue Fever (DF) by Products in France

#### 12.3.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.4 Market Size of Dengue Fever (DF) in Italy

#### 12.4.1 Market Size of Dengue Fever (DF) in Italy

#### 12.4.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in Italy

#### 12.4.3 Market Sales of Dengue Fever (DF) by Products in Italy

#### 12.4.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.5 Market Size of Dengue Fever (DF) in Spain

#### 12.5.1 Market Size of Dengue Fever (DF) in Spain

#### 12.5.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in Spain

#### 12.5.3 Market Sales of Dengue Fever (DF) by Products in Spain

#### 12.5.4 Analysis of Upcoming Therapies and Impact on the Market

### 12.6 Market Size of Dengue Fever (DF) in United Kingdom

#### 12.6.1 Market Size of Dengue Fever (DF) in United Kingdom

#### 12.6.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in United Kingdom

#### 12.6.3 Market Sales of Dengue Fever (DF) by Products in United Kingdom

#### 12.6.4 Analysis of Upcoming Therapies and Impact on the Market

## 13 THE JAPAN MARKET OUTLOOK

### 13.1 Market Size of Dengue Fever (DF) in Japan

### 13.2 Percentage Share of Drugs Marketed for Dengue Fever (DF) in Japan

### 13.3 Market Sales of Dengue Fever (DF) by Products in Japan

### 13.4 Analysis of Upcoming Therapies and Impact on the Market

## 14 COST ANALYSIS OF DENGUE FEVER (DF)

## **15 GENERIC COMPETITION IN DENGUE FEVER (DF) MARKET**

## **16 MARKET DRIVERS**

## **17 MARKET BARRIERS**

## **18 REPORT METHODOLOGY**

### 18.1 Methodology/Research Approach

### 18.2 Data Source

#### 18.2.1 Secondary Sources

#### 18.2.2 Primary Sources

## I would like to order

Product name: Dengue Fever (DF)- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/D079104FD09EN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D079104FD09EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970